The Neuro4D Conference 2019

Favorite Park Hotel – Mainz, Germany – Close to Frankfurt Airport

Neuro4D

**DEGENERATIVE
DISEASE
DRUG
DISCOVERY**

8:00		
Registration and Joint Breakfast		
9:00		
Opening of the Conference		
9:15		
Scientific Introduction Parkinson's Disease	Targeting LRRK2 in Parkinson's disease	**Andrew West** Duke Center for Neurodegeneration Research, Durham, USA
PANEL 09:45 – 10:45		
PD Disease Mechanism	Animal Models and Mechanisms of LRRK2 and VPS35 in Parkinson's Disease	**Darren Moore** Van Andel Research Institute, Grand Rapids, USA
	A pyroglutamate-modified α-synuclein fragment in Parkinson's disease brain	**Steffen Roßner** Paul-Flechsig-Institute for Brain Research, Leipzig, Germany
	Is Parkinson's disease caused by synaptic decline rather than neuronal death?	**Walter Schulz-Schaeffer** Saarland University, Homburg (Saar), Germany
Panel Q&A of Session Speakers *Chair: Andrew West, Duke Center for Neurodegeneration Research, Durham, USA*		
10:45		
Coffee Break, Exhibition & Poster Session (all Presenters will be at their Posters for Discussion)		
PANEL 12:00 – 13:00		
PD Model	Animal models of α-synucleinopathy for Parkinson's disease drug development	**James Koprich** Atuka Inc., Toronto, Canada
PD Drug Discovery	Defining Novel Targets for Cognitive Impairment in Parkinson's Disease	**Tiago Outeiro** Exp. Neurodegeneration, University of Göttingen, Germany
	Using computer modeling to accelerate drug discovery for Parkinson's disease: Insights from genetics and transcriptomics	**Spring Behrouz** NeuroInitiative, Jacksonville, USA
Panel Q&A of Session Speakers *Chair: Andrew West, Duke Center for Neurodegeneration Research, USA*		
13:00		
Lunch		

The Neuro4D Conference 2019

Favorite Park Hotel – Mainz, Germany – Close to Frankfurt Airport

Neuro 4D — **D**EGENERATIVE **D**ISEASE **D**RUG **D**ISCOVERY

MONDAY MAY 13TH

	14:00	
Scientific Introduction Alzheimer's Disease	The search for alternative β-secretases	**Hans-Ulrich Demuth** Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany
	PANEL 14:30 – 15:30	
AD Disease Mechanism	Post-translational modifications of Aβ peptides in distinct aggregation pathways and the progression of Alzheimer's disease	**Jochen Walter** University of Bonn Medical Center, Bonn, Germany
Neurodegeneration Model	An in vivo tau seeding and spreading model in mice	**Bart Roucourt** Remynd, Leuven, Belgium
	Generation and characterization of a human tau knock-in mouse	**Holger Cynis** Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany

Panel Q&A of Session Speakers
Chair: Hans-Ulrich Demuth, Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany

15:30
Coffee Break, Exhibition & Poster Session (all Presenters will be at their Posters for Discussion) **One on One Meetings**

	PANEL 17:00 – 18:00	
AD Drug Discovery	IsoAspartate-Aβ specific antibody attenuates Alzheimer's Disease-like pathology in transgenic mice	**Stephan Schilling** Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany
	The first anti-prionic directly disassembles Aβ oligomers and reverses cognition deficits in old TG AD mice and is safe in humans	**Dieter Willbold** Priavoid, Jülich, Germany
	Repurposing igmesine for the treatment of neuro-degenerative diseases	**François J. Roman** Amylgen, Montferrier, France

Panel Q&A of Session Speakers
Chair: Hans-Ulrich Demuth, Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany

18:00
Wine Tasting

19:00 – 22:00
Dinner

END OF THE FIRST DAY

The Neuro4D Conference 2019

Favorite Park Hotel – Mainz, Germany – Close to Frankfurt Airport

Neuro 4D
DEGENERATIVE
DISEASE
DRUG
DISCOVERY

8:00		
Joint Breakfast		
8:30		
Scientific Introduction	Prion-like spreading of cross-seeded protein aggregates	**Rakez Kayed** Department of Neurology, University of Texas, Galveston, USA
PANEL 9:00 – 10:15		
Prion-Mechanism	Prion-like propagation in systemic amyloidosis	**Marcus Fändrich** Protein Biochemistry, Ulm University, Germany
ALS Drug Discovery	D-enantiomeric peptides for the treatment of ALS	**Antje Willuweit** Inst. F. Neurosciences & Medcine, Jülich, Germany
Drug Discovery Tools	Flavours of α-synuclein and tau-fibrillization and activity of protein aggregates as drug discovery tools	**Alexandra Netter-Glangeaud** Stressmarq, Victoria, Canada
	Chemoproteomics profiling of HDAC inhibitors for synaptopathies	**Hannes Hahne** OmicScouts, Freising, Germany

Panel Q&A of Session Speakers
Chair: Rakez Kayed, University of Texas, USA

10:15		
Coffee Break, Exhibition & Poster Session *(all Presenters will be at their Posters for Discussion)* **One on One Meetings**		
11:00		
Drug Discovery	Stimulating neurogenesis for treatment of neurodegenerative diseases	**Georg C. Terstappen** CSO at OxStem, Oxford, UK
11:20		
Cognition Models	Back to the future: The importance of cognitive preclinical models for Alzheimer's disease	**Joseph Araujo** InterVivo Solutions, Toronto, Canada
11:40		
Cognition Models	Using machine learning approaches to identify symptomatic treatments for neurodegenerative diseases	**Emer Leahy** Psychogenics, New York City, USA
12:00		
Lunch		

The Neuro4D Conference 2019

Favorite Park Hotel – Mainz, Germany – Close to Frankfurt Airport

Neuro 4D

DEGENERATIVE DISEASE DRUG DISCOVERY

TUESDAY MAY 14TH

13:00		
Current State of Drug Discovery in Neurodegenerative Diseases	A role for mutant ubiquitin in amyloid-β seeding?	**Fred van Leeuwen** Maastricht University, The Netherlands

13:30		
Clinical Development	Reviewing clinical trials for AD: Will patients finally benefit from current drug candidates?	**Oliver Peters** Charité, Berlin, Germany

14:00

Coffee Break, Exhibition and Posters
(all Presenters will be at their Posters for Discussion)
One on One Meetings

15:00

Panel Discussion:

How can we achieve translational drug discovery in neurodegenerative diseases and convince strategic partners and investors to invest?

- How can we get trust in translational animal models of neurodegeneration again?
- More and more international pharma companies are dropping neurodegenerative diseases for 'lack of progress' after losing multi-billion dollar investments. However, there is a need for deep pockets to pay for the late clinical trials of disease-modifying drugs. How can we raise interest levels in new approaches again?
- What is a patient, caretaker and payer relevant disease improvement?

Participants: Drug Discovery Companies, Service Providers and Innovators

16:00 – 16:15

Summary and wrap-up of the conference

END OF THE CONFERENCE AND DEPARTURE

Major Sponsors

InterVivo SOLUTIONS   **IN VIVO DRUG DISCOVERY amylgen**   **StressMarq Biosciences INC.**